GlassScriptPhysician profile
Shane Patrick Dorsey
NPI 1346700903
$799.66
in general payments reported to CMS, 2019-2025
14 companies · $30.03 in 2025
The $30.03 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $38.17 · 2022: $249 · 2023: $320 · 2024: $162 · 2025: $30.03.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $512.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $512.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $188.19 | 2022-2025 | Botox |
| Teva Pharmaceuticals USA, INC. | $162.09 | 2023-2024 | Austedo, Austedo Xr |
| Ucb, INC. | $91.56 | 2022-2023 | Briviact |
| Lundbeck LLC | $84.40 | 2023-2024 | Vyepti, Rexulti |
| Horizon Therapeutics Plc | $41.85 | 2022-2023 | Uplizna |
| Astrazeneca Pharmaceuticals LP | $38.17 | 2021 | |
| Tanabe Pharma America, INC. | $33.99 | 2023 | |
| Amgen INC. | $30.92 | 2024 | Uplizna |
| Pfizer INC. | $27.81 | 2024 | |
| Jazz Pharmaceuticals INC. | $23.43 | 2023 | |
| Argenx US, INC. | $23.35 | 2023 | Vyvgart |
| Neurocrine Biosciences, INC. | $19.90 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $19.78 | 2024 | Rexulti |
| Biogen, INC. | $14.22 | 2023 | Plegridy, Vumerity, Avonex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shane Dorsey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.